This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
PhenomeX Inc. (CELL) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
PhenomeX Inc. (CELL) delivered earnings and revenue surprises of -11.11% and 3.52%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Acadia Pharmaceuticals (ACAD) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Acadia (ACAD) delivered earnings and revenue surprises of -28.57% and 2.66%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
NGM Biopharmaceuticals (NGM) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of -11.54% and 67.55%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Immatics (IMTX) Moves 27.5% Higher: Will This Strength Last?
by Zacks Equity Research
Immatics (IMTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Immatics (IMTX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Immatics (IMTX) delivered earnings and revenue surprises of -3.23% and 13.62%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ginkgo Bioworks Holdings, Inc. (DNA) delivered earnings and revenue surprises of -60% and 22.33%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Tango Therapeutics, Inc. (TNGX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Tango Therapeutics, Inc. (TNGX) delivered earnings and revenue surprises of -3.13% and 15.99%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Vericel Corporation (VCEL) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Vericel Corporation (VCEL) delivered earnings and revenue surprises of -16.67% and 3.68%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Does Immatics (IMTX) Have the Potential to Rally 77% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 76.9% in Immatics (IMTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts See an 81% Upside in Immatics (IMTX): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Immatics (IMTX) points to an 81.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Immatics (IMTX) Moves 11.6% Higher: Will This Strength Last?
by Zacks Equity Research
Immatics (IMTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Wall Street Analysts Think Immatics (IMTX) Could Surge 82%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 81.5% in Immatics (IMTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Immatics (IMTX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Immatics (IMTX) delivered earnings and revenue surprises of -276.92% and 56.96%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Voyager Therapeutics (VYGR) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 10.71% and 71.52%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Immatics (IMTX): Can Its 18% Jump Turn into More Strength?
by Zacks Equity Research
Immatics (IMTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Immatics (IMTX) Stock Jumps 5.2%: Will It Continue to Soar?
by Zacks Equity Research
Immatics (IMTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
BMY, IMTX Extend Deal to Develop Cell Therapies for Cancer
by Zacks Equity Research
Bristol Myers (BMY) strengthens its partnership with the small biotech company Immatics (IMTX) to develop multiple allogenic cell therapies targeting multiple cancer indications.
Immatics (IMTX) Lags Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Immatics (IMTX) delivered earnings and revenue surprises of -18.28% and 23.88%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
HOOKIPA Pharma Inc. (HOOK) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
HOOKIPA Pharma Inc. (HOOK) delivered earnings and revenue surprises of -233.33% and 93.14%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Immatics (IMTX): Can Its 5.3% Jump Turn into More Strength?
by Zacks Equity Research
Immatics (IMTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Wave Life Sciences (WVE) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Wave Life Sciences (WVE) delivered earnings and revenue surprises of -10.71% and 53.33%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Geron (GERN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Geron (GERN) delivered earnings and revenue surprises of 18.18% and 23%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts See a 178% Upside in Immatics (IMTX): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 178.1% upside potential for Immatics (IMTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Immatics (IMTX) Stock Jumps 5.8%: Will It Continue to Soar?
by Zacks Equity Research
Immatics (IMTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.